Últimas noticias sobre Sezzle (NASDAQ:SEZL) Bolsa

Sezzle

Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

HRTG

SEZL

Sezzle y Heritage Insurance muestran señales de sobrecompra con RSI altos. ¿Es hora de vender? Descubre lo que significa para los inversores.

2 acciones financieras que podrías considerar vender en agosto

Sezzle Inc

PIXY

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<p>Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) has outperformed the market over the past 15 years by 7.37% on an annualized basis producing an average annual return of 19.1%. Currently, Ameriprise Finl has a market capitalization of $49.45 billion. </p>
<p><strong>Buying $1000 In AMP:</strong> If an investor had bought $1000 of AMP stock 15 years ago, it would be worth <strong>$13,919.67</strong> today based on a price of $502.50 for AMP at the time of writing.</p>
<h3>Ameriprise Finl's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728682223_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Ameriprise Finl Stock In The Last 15 Years

<p>Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 10.53% on an annualized basis producing an average annual return of 24.69%. Currently, Pure Storage has a market capitalization of $17.43 billion. </p>
<p><strong>Buying $100 In PSTG:</strong> If an investor had bought $100 of PSTG stock 5 years ago, it would be worth <strong>$305.05</strong> today based on a price of $53.20 for PSTG at the time of writing.</p>
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728682218_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PSTG

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

ZPTAW

Trading Halt: Halt status updated at 5:30:00 PM ET: Quotation Resumption: News and Resumption Times

ZPTA

Trading Halt: Halt status updated at 5:25:00 PM ET: Quotation Resumption: News and Resumption Times

<p>JP Morgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>) and Wells Fargo &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wfc#NYSE">WFC</a>) ended the week by reporting their quarterly results, kicking off the third quarter earnings season.&nbsp;Bank of America Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) is due to report its latest financial results on Tuesday, with The Goldman Sachs Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>), Citigroup Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) and Morgan Stanley(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ms#NYSE">MS</a>)&nbsp;due to also report next week.</p>
<h3>JP Morgan Reported A&nbsp;Better-Than-Expected Interest Income&nbsp;</h3>
<p>During the quarter ended in September, JP Morgan reported&nbsp;revenues rose 6% YoY to $43.3 billion, surpassing LSEG&rsquo;s consensus estimate of&nbsp;$41.63 billion. Results were fueled by investment banking fees that grew 31% as they brought in $2.27 billion.</p>
<p>On the other hand, JP Morgan reported that&nbsp;net income fell 2%&nbsp;to $12.9 billion, but earnings per share rose to $4.37, up from $4.33 as there were fewer outstanding shares in the latest quarter, surpassing FactSet&rsquo;s consensus estimate of $3.99 a share.</p>
<p>However,&nbsp;net interest income grew 3% to $23.5 billion, surpassing both StreetAccount&rsquo;s estimate of $22.73 billion and&nbsp;FactSet&rsquo;s estimate of $22.9 billion. Consequently, JP Morgan raised its full year guidance for net interest income up from $91 billion to about&nbsp;$92.5 billion.&nbsp;</p>
<p>JP Morgan has et aside more money to cover credit losses, more precisely $3.1 billion, compared ot last year&rsquo;s comparable quarter when it had only set aside $1.4 billion.</p>
<p>During the earnings call, CFO&nbsp;Jeremy Barnum&nbsp;described the consumer is doing fine&nbsp;and is on a solid footing.&nbsp;But CEO Jamie Dimon spoke of continuously monitoring geopolitical tensions that he described as &ldquo;treacherous and getting worse.&rdquo;&nbsp;In a statement where he referred to the unspeakable human suffering, with the outcome of conflicts possibly having far-reaching effects on both short-term economic outcomes and more importantly, the course of history.&nbsp;Dimon is one of the rare CEOs who goes beyond the scope of banking to view the bigger picture of the world, often giving solicited or unsolicited advice to global leaders.</p>
<p>All in all, the biggest American bank continues to thrive&nbsp;in a rising rate environment.</p>
<p>Wells Fargo continues to evolve and generate more income through fees.&nbsp;</p>
<p>Wells Fargo reported third-quarter revenue dropped to $20.37&nbsp;billion, reporting a profit of $1.42 per share as net income fell to&nbsp;$5.11 billion. Net interest income also fell 11% to&nbsp;$11.69 billion, but&nbsp;the decline was offset by higher fee income.</p>
<p>However, the bigger picture here is that the once the country&rsquo;s #1 home mortgage lender has evolved in recent years.</p>
<p>Earlier this year, the Biden administration lifted a consent order that was in place since 2016&nbsp;&nbsp;following a series of scandals that included fake customer accounts.&nbsp;Last month, Wells Fargo even agreed to work with U.S. bank regulators to improve its financial crimes risk management controls that detect suspicious activity and money laundering.&nbsp;The bottom line is that despite the YoY decline of both profit and revenue, they fell less than analysts had expected.&nbsp;</p>
<p>By reporting better than feared results, both Wells Fargo and JP Morgan have shown that the U.S. consumers proved to be more resilient than expected, suggesting that a soft landing is more likely than a recession.&nbsp;</p>
<p><em>DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.</em></p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</em></p>


General

JP Morgan And Wells Fargo Report Better Than Expected Q3 Results That Reflect Resilient U.S. Consumers

<p>STOCK CLIMBS 1.5% AT HIGH POINT</p>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="818" height="795" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM.png" alt="" class="wp-image-2234" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM.png 818w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM-300x292.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/11200904/Screen-Shot-2024-10-11-at-4.12.03-PM-768x746.png 768w" sizes="(max-width: 818px) 100vw, 818px" /></figure></p>
<p><strong>MercadoLibre, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. </p>
<p>Today, at <strong>10:37 AM on OCTOBER  11th</strong>, a significant trading signal occurred for <strong>MercadoLibre, Inc. </strong>as it demonstrated a Power Inflow at a price of <strong>$2074.55.</strong> This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in MercadoLibre&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Mercado Libre&#8217;s stock price, interpreting this event as a bullish sign.</p>
<p><strong>Signal description</strong></p>
<p>Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. <em>This particular indicator is interpreted as a bullish signal by active traders.</em>&nbsp;</p>
<p>The Power Inflow occurs within the first two hours of the market open. Generally, it signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;</p>
<p>By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success</p>
<p>If you want to stay updated on the latest options trades for <strong>MELI</strong>, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;</p>
<p><a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article.<br /></p>
<p>&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</p>
<p><strong><em>After Market Close UPDATE</em>:</strong></p>
<p>The price at the time of the Power Inflow was <strong>$2074.55.</strong> The returns on the High price (<strong>$2105.33</strong>) and Close price (<strong>$2091.28</strong>) after the Power Inflow are respectively <strong>1.5% </strong>and <strong>0.8%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite</strong>.</p>


Signals

MELI

Tradepulse Power Inflow Alert: Mercadolibre Inc. Rises Over 30 Points After Signal

<p>Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Edgewell Personal Care, presenting an average target of $39.5, a high estimate of $41.00, and a low estimate of $37.00. A decline of 3.07% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680505_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Edgewell Personal Care by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edgewell Personal Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edgewell Personal Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Edgewell Personal Care's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Edgewell Personal Care's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EPC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Edgewell Personal Care analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Edgewell Personal Care</h2>
<p>Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.</p>
<h3>Edgewell Personal Care's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Edgewell Personal Care's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.34%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Edgewell Personal Care's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.56%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Edgewell Personal Care's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.13%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Edgewell Personal Care's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.31%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.83</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Navigating 4 Analyst Ratings For Edgewell Personal Care

<p>In the latest quarter, 6 analysts provided ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.33, along with a high estimate of $111.00 and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 4.58% from the previous average price target of $101.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680490_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Eastman Chemical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$111.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$107.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Eastman Chemical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eastman Chemical's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Eastman Chemical analyst ratings.</strong></a></p>
<h2>All You Need to Know About Eastman Chemical</h2>
<p>Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.</p>
<h3>Key Indicators: Eastman Chemical's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Eastman Chemical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>1.68%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>9.73%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.12%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eastman Chemical's ROA excels beyond industry benchmarks, reaching <strong>1.55%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Eastman Chemical's debt-to-equity ratio is below the industry average at <strong>0.89</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Eastman Chemical Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<p>In the preceding three months, 18 analysts have released ratings for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for UnitedHealth Group, revealing an average target of $615.78, a high estimate of $680.00, and a low estimate of $591.00. Observing a 6.75% increase, the current average has risen from the previous average price target of $576.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680474_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of UnitedHealth Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$675.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$680.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>David Toung</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$601.00</td>
<td>$546.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$604.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$591.00</td>
<td>$591.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$630.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$640.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$615.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$647.00</td>
<td>$481.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$640.00</td>
<td>$597.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$615.00</td>
<td>$595.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for UnitedHealth Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into UnitedHealth Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UNH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on UnitedHealth Group analyst ratings.</strong></a></p>
<h2>Discovering UnitedHealth Group: A Closer Look</h2>
<p>UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<h3>UnitedHealth Group's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> UnitedHealth Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>6.61%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> UnitedHealth Group's net margin excels beyond industry benchmarks, reaching <strong>4.31%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> UnitedHealth Group's ROE excels beyond industry benchmarks, reaching <strong>4.79%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.48%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.84</strong>, UnitedHealth Group faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring UnitedHealth Group Through Analyst Insights

<p>Analysts' ratings for Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Encompass Health, revealing an average target of $106.0, a high estimate of $115.00, and a low estimate of $100.00. Surpassing the previous average price target of $100.57, the current average has increased by 5.4%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680459_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Encompass Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Encompass Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Encompass Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Encompass Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Encompass Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Encompass Health analyst ratings.</strong></a></p>
<h2>About Encompass Health</h2>
<p>Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.</p>
<h3>Encompass Health: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Encompass Health's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>9.61%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Encompass Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.71%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Encompass Health's ROE excels beyond industry benchmarks, reaching <strong>6.33%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Encompass Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.8%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.6</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 8 Analyst Evaluations For Encompass Health

<p>Ratings for eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.84, a high estimate of $70.00, and a low estimate of $46.00. Surpassing the previous average price target of $55.94, the current average has increased by 8.76%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680450_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive eBay is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$46.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$59.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to eBay. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of eBay compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for eBay's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into eBay's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EBAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on eBay analyst ratings.</strong></a></p>
<h2>Discovering eBay: A Closer Look</h2>
<p>EBay operates one of the largest e-commerce marketplaces in the world, with $73 billion in 2023 gross merchandise volume, or GMV, rendering the firm a top 10 global e-commerce company. The company generates revenue from listing fees, advertising, revenue-sharing arrangements with service providers, and managed payments, with its platform connecting more than 130 million buyers and roughly 20 million sellers across almost 190 global markets at the end of 2023. EBay generates just north of 50% of its GMV in international markets, with a large presence in the UK, Germany, and Australia.</p>
<h3>Key Indicators: eBay's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> eBay displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>1.26%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>8.71%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> eBay's ROE excels beyond industry benchmarks, reaching <strong>3.8%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.07%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> eBay's debt-to-equity ratio is below the industry average. With a ratio of <b>1.48</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EBAY

Key Takeaways From eBay Analyst Ratings

<p>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.29% on an annualized basis producing an average annual return of 13.91%. Currently, Centene has a market capitalization of $38.08 billion. </p>
<p><strong>Buying $100 In CNC:</strong> If an investor had bought $100 of CNC stock 20 years ago, it would be worth <strong>$1,305.23</strong> today based on a price of $72.39 for CNC at the time of writing.</p>
<h3>Centene's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680441_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Centene 20 Years Ago Would Be Worth Today

<p>MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) has outperformed the market over the past 5 years by 2.61% on an annualized basis producing an average annual return of 16.77%. Currently, MongoDB has a market capitalization of $21.64 billion. </p>
<p><strong>Buying $1000 In MDB:</strong> If an investor had bought $1000 of MDB stock 5 years ago, it would be worth <strong>$2,129.19</strong> today based on a price of $293.00 for MDB at the time of writing.</p>
<h3>MongoDB's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680436_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

<p>Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.0, a high estimate of $28.00, and a low estimate of $24.00. A 4.2% drop is evident in the current average compared to the previous average price target of $27.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728680416_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Atlas Energy Solutions's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Atlas Energy Solutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Atlas Energy Solutions compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Atlas Energy Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Atlas Energy Solutions's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AESI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Atlas Energy Solutions analyst ratings.</strong></a></p>
<h2>About Atlas Energy Solutions</h2>
<p>Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.</p>
<h3>Atlas Energy Solutions: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Atlas Energy Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>77.71%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Atlas Energy Solutions's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>5.16%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Atlas Energy Solutions's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.39%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Atlas Energy Solutions's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.76%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.47</strong>, Atlas Energy Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AESI

Decoding 7 Analyst Evaluations For Atlas Energy Solutions

<p>Cryptocurrency markets were trading higher before entering the weekend with altcoins also being pushed up.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$63,000.44</td>
<td>+5.8%</td>
</tr>
<tr>
<td><strong>Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,459.54</td>
<td>+4.3%</td>
</tr>
<tr>
<td><strong>Solana </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$145.88</td>
<td>+6.2%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.111</td>
<td>+6.2%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001775</td>
<td>+8.2%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<h1 class="wp-block-heading"><strong>Notable Statistics:</strong></h1>
<ul>
<li>IntoTheBlock data showed large transaction volume decreasing by 23.2% and daily active addresses up by 3.6%. Transactions greater than $100,000 were up from 7,555 to 8,264 in a single day. Exchanges netflows were down by 327.6%. Currently, 87% of Bitcoin holders made profits while 13% were at breakeven.</li>
<li>Coinglass data reported 38,216 traders were liquidated in the past 24 hours with the total liquidations at $115.88 million.</li>
</ul>
<h1 class="wp-block-heading"><strong>Notable Developments:</strong></h1>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41297376/bitcoin-will-hit-250k-raoul-pal-says-why-the-gurus-top-5-crypto-predictions-matter-if-your">Bitcoin Will Hit $250K, Raoul Pal Says: Why The Guru&#8217;s Top 5 Crypto Predictions Matter If &#8216;You&#8217;re A Wage Slave&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41285570/tron-founder-justin-sun-appointed-prime-minister-of-a-crypto-focused-micronation-in-europe">Tron Founder Justin Sun Appointed &#8216;Prime Minister&#8217; Of A Crypto-Focused Micronation In Europe</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41297899/kamala-harris-receives-1-million-in-xrp-from-ripple-co-founder-chris-larsen">Kamala Harris Receives $1 Million In XRP From Ripple Co-Founder Chris Larsen</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41285163/tesla-themed-coins-spike-after-ev-giant-unveils-cybercab-robotaxi-why-you-should-be-carefu">Tesla-Themed Coins Spike After EV Giant Unveils &#8216;Cybercab&#8217; Robotaxi — Why You Should Be Careful</a></li>
</ul>
<h1 class="wp-block-heading"><strong>Top Gainers:</strong></h1>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Ethena </strong>(CRYPTO: ENA)</td>
<td>&nbsp;$0.3366</td>
<td>+25.2%</td>
</tr>
<tr>
<td><strong>Mog Coin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>)</td>
<td>&nbsp;$0.0<sub>5</sub>1709&nbsp;</td>
<td>+24.2%</td>
</tr>
<tr>
<td><strong>Worldcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WLD</a>)</td>
<td>&nbsp;$1.93</td>
<td>+14.9%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>With Bitcoin prices trading higher beyond $62,000, crypto trader <strong>Javon Marks</strong> saw the crypto king still looking to reclaim its all-time highs of $73,700. Also, based on historical performance of a similar pattern, prices could also be set for a move much higher. He <a href="https://x.com/JavonTM1/status/1844741428028625321">predicted</a> the next target at $116,650.</p>
<p>Crypto analyst <strong>Miles Deutscher </strong>marked $59,000 as must hold level. He predicted not making any "major moves this weekend (apart from trading memes), as directionality is still a bit unclear."</p>
<p>He <a href="https://x.com/milesdeutscher/status/1844788856643592468">added</a> there needed to be a higher high to officially break downtrend structure.</p>
<p><strong>Michael van de Poppe</strong> highlighted the trend switched and the next test is at $65,000.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The trend has switched!<br /><br />Despite the current sentiment, markets are already uptrending and I think that the acceleration is just around the corner for the whole market.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> made a higher, higher low, and found support at $60K.<br /><br />The next test at $65K, that&#39;s the one. <a href="https://t.co/CaU3jrFeSW">pic.twitter.com/CaU3jrFeSW</a></p>
<p>&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1844800136855044167?ref_src=twsrc%5Etfw">October 11, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Another crypto trader <strong>Seth</strong> <a href="https://x.com/seth_fin/status/1844813140866810204">advised</a> to not make any mistakes as the bull market is going on. He noted whales were accumulating and grabbing liquidity from the retail traders. He predicted the liquidity will help "ascend."</p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41295451/bitcoin-rises-2-to-break-62k-trader-reports-90-to-100-bullish-signals">Bitcoin Rises 2% to Break $62K, Trader Reports &#8216;90% to 100% Bullish Signals&#8217;</a></strong></li>
</ul>
<p><em>Photo: Avi Rozen on Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$MOG

$SHIB

$SOL

$WLD

Bitcoin, Ethereum, Dogecoin See Friday Gains, But Trader Warns '$59,000 Must Hold, No Major Moves Expected This Weekend'

<p>As Florida's pivotal vote on recreational cannabis looms, investors are eyeing key opportunities in the market. The<strong> Viridian Credit Tracker</strong> ranks <strong>AYR Wellness</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) as a strong buy, with a compelling 20% yield driven by its significant presence in Florida's cannabis market. With the potential for Florida voters to approve recreational use, AYR stands to gain considerably, making it a prime target for investors before the vote.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</em></strong></li>
</ul>
<h3 class="wp-block-heading">AYR Wellness Offers 20% Yield: Capitalize on Florida's Potential Vote</h3>
<p>According to the Viridian Credit Tracker from <strong><a href="https://www.benzinga.com/topic/viridian-capital-advisors">Viridian Capital Advisors</a></strong>, AYR's exposure to Florida's market gives it a unique advantage ahead of the state&#8217;s potential legalization of recreational cannabis. </p>
<p>With a 20% trading yield, AYR outpaces many of its competitors. If <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a> approves recreational cannabis, AYR's valuation could see a substantial boost, making this stock a strategic buy for investors ahead of the vote.</p>
<h3 class="wp-block-heading">Cresco Labs vs. Curaleaf: A 250 Basis Point Difference</h3>
<p>Another <a href="https://dealtracker.viridianca.com/credit-tracker-by-industry-sector/">suggested pair trade</a> from the report is to buy <strong>Cresco Labs</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) at a 12.6% yield and sell <strong>Curaleaf </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) at 10.1%. This trade offers investors a 250 basis point yield upgrade, backed by Cresco's solid financials and credit improvement. Investors looking for higher returns and credit strength should consider this opportunity.</p>
<p><strong>Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41277104/exclusive-80-growth-despite-the-chaos-how-dutchie-c3-defy-2024s-cannabis-slump"> EXCLUSIVE: 80% Growth Despite The Chaos: How Dutchie, C3 Defy 2024&#8217;s Cannabis Slump</a></strong></p>
<h3 class="wp-block-heading">TerrAscend: Why 12% Yield Might Not Be Enough</h3>
<p>In contrast, <strong>TerrAscend </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRSSF#OTC">TRSSF</a>), which offers a 12% yield, is <a href="https://dealtracker.viridianca.com/credit-tracker-by-industry-sector/">recommended as a sell</a>. While TerrAscend remains a significant player in the cannabis industry, its lower yield and reduced exposure to Florida's growth potential make it less appealing compared to AYR.</p>
<h3 class="wp-block-heading">Cannabist Faces Liquidity Challenges</h3>
<p>Despite the attractive spreads among top stocks, <strong>Cannabist</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>) ranks as the <a href="https://www.benzinga.com/markets/cannabis/24/10/41192369/lender-expresses-concern-over-cannabist-companys-pray-and-hope-approach">weakest credit in the group</a>, largely due to liquidity concerns following recent asset sales. Investors should note that Cannabist's lower credit rating may limit its near-term upside despite potential improvements in the future.</p>
<h3 class="wp-block-heading">Take Action Now: Florida's Vote Could Change the Game</h3>
<p>With Florida's cannabis market potentially expanding, investors looking to maximize gains should consider this pair trade: buy AYR at 20%, sell TerrAscend at 12%, and look into Cresco Labs at 12.6% versus Curaleaf at 10.1%. The <a href="https://www.benzinga.com/markets/cannabis/24/10/41240793/its-your-constitutional-right-how-you-can-break-the-senates-block-on-cannabis-legalization">vote could transform the landscape for cannabis stocks</a>, and taking action before this pivotal event could provide substantial returns.</p>
<p><figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="583" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024.jpg" alt="" class="wp-image-590060" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024.jpg 583w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10141616/Viridian-Capital-Advisors-Viridian-Credit-Tracker-October-2024-300x281.jpg 300w" sizes="(max-width: 583px) 100vw, 583px" /><figcaption class="wp-element-caption"><em>Courtesy of Viridian Capital Advisors </em></figcaption></figure></p>
<p><strong>Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41270886/sec-charges-magic-mushroom-co-minerco-in-8m-pump-and-dump-scheme"> SEC Charges &#8216;Magic Mushroom&#8217; Co. Minerco In $8M Pump-And-Dump Scheme</a></strong></p>


Analyst Color

Cannabis

Small Cap Analysis

Technicals

Small Cap

AYRWF

CCHWF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

TRSSF

Why Cannabis Investors Should Make This Bold Move Before Florida's Vote: What To Buy And Sell Now

Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending

<p><strong>Bedrocan International,</strong> a producer of pharmaceutical-grade medicinal cannabis, is set to make a return to the Canadian market, reaffirming its long-held commitment to providing standardized medicinal cannabis for patients. The company recently acquired a facility in Scarborough, a strategic location that once served as its operational base in Canada, and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking Bedrocan's renewed presence in Canada after several years of absence.</p>
<p>"We have had a strictly pharmaceutical approach since our foundation in 2003. We use the knowledge we have acquired in more than twenty years of business to produce cannabis products that benefit patients exclusively," said Bedrocan's CEO <strong>Jaap Erkelens</strong>. Bedrocan's meticulous approach to production ensures consistent levels of THC and CBD in all of its products, offering patients a reliable, standardized therapeutic experience. This level of precision is critical for both patients and prescribing physicians who seek consistent outcomes from medical cannabis treatments.</p>
<p>In its return to the Canadian market, Bedrocan aims to introduce several of its standardized cannabis products, with the Bedrocan brand at the forefront. The company plans to distribute these products via a third party through the medical sales channel, providing registered patients with direct access to high-quality, medicinal cannabis.</p>
<p>The company's return follows a previous venture in Canada that ended with the termination of its partnership with <strong>Canopy Growth Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>). Despite this setback, Bedrocan remained steadfast in its desire to return to the Canadian market. "We are thrilled to be coming back to Canada," Erkelens said. "We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape."</p>
<p><em>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p>Cover image made with AI</p>


European Cannabis Giant Bedrocan To Re-Enter Canadian Market With Pharmaceutical-Grade Products, New Facility

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The <strong>Nasdaq 100</strong> has more than doubled over the past five years. It&rsquo;s filled with the top 100 non-financial Nasdaq stocks based on market cap. This benchmark contains some of the best Nasdaq stocks, based on its ability to consistently outperform the <strong>Nasdaq Composite</strong> in bullish markets.</p>



<p>Looking at the stocks within a top-performing benchmark can help you generate higher returns. By definition, a benchmark continues stocks that have outperformed its year-to-date returns. You can find the first two stocks on this list within the Nasdaq 100, and unsurprisingly, they are tech companies.</p>



<p>However, the third company on this list is much smaller. It has a market cap below $1 billion, but the fintech company has crushed the stock market year-to-date. The company has enticing growth opportunities and a reasonable valuation. This small company and the two tech giants demonstrate the level of range that you will find in the Nasdaq. Ready for the list? These are some of the best Nasdaq stocks to consider.</p>



<h2>Meta Platforms (META)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/meta1600-1-300x169.png" alt="In this photo illustration the Meta logo seen displayed on a smartphone and in the background the Facebook logo"><div>Source: rafapress / Shutterstock.com</div></div><p><strong>Meta Platforms</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/meta-stock-quote/"><strong>META</strong></a>) has been outpacing the stock market for several years. Facebook, Instagram, and WhatsApp have become the social networks of choice for many consumers. The vast demand for Meta Platforms&rsquo; social networks plus the attention they retain has led to serious gains for investors.&nbsp;</p>



<p>The tech giant has outperformed the Nasdaq year-to-date and over the past five years. Recent earnings results suggest that the trend will continue. Meta Platforms delivered 22% YOY revenue growth in the <a href="https://s21.q4cdn.com/399680738/files/doc_financials/2024/q2/Meta-06-30-2024-Exhibit-99-1_Final.pdf">second quarter</a> while net income jumped by 73% YOY. The&nbsp; company closed out the quarter with 3.27 billion daily active users which is a 7% YOY increase.</p>



<p>Meta Platforms excited investors at the end of last year by initiating a dividend program. The company distributed $1.27 billion to investors as dividend payouts and repurchased $6.32 billion worth of shares. Meta Platforms has the financial strength and growth rates to suggest that the dividend can maintain a double-digit growth rate for several years.</p>



<h2>Broadcom (AVGO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/avgo1600-1-300x169.png" alt="Person holding cellphone with logo of US semiconductor company Broadcom Inc. (AVGO) on screen in front of business webpage. Focus on phone display. Unmodified photo. Broadcom stock"><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Broadcom</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/"><strong>AVGO</strong></a>) is one of the top AI beneficiaries that has been expanding its market share. The company generated a record $3.1 billion from its AI products and services in the <a href="https://investors.broadcom.com/news-releases/news-release-details/broadcom-inc-announces-second-quarter-fiscal-year-2024-financial">second quarter of fiscal 2024</a>. The company also reported 43% YOY revenue growth across its entire business. The <strong>VMware</strong> acquisition was a major contributor, but the company still generated 12% YOY revenue growth excluding VMware. More enterprise customers have adopted the VMware software stock to build private clouds.</p>



<p>The stock has outperformed the stock market year-to-date and over the past five years. It also offers a generous dividend yield of roughly 1.50%. Shares are in the middle of a correction right now, so there&rsquo;s a chance that the yield gets higher. Broadcom has a good reputation of dividend hikes that includes a double-digit growth rate for several years.&nbsp;</p>



<p>Wall Street analysts are bullish on the stock. Broadcom is rated as a <a href="https://www.tipranks.com/stocks/avgo/forecast">Strong Buy</a> with a projected 37% upside from current levels.</p>



<h2>Sezzle (SEZL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/buy-now-pay-later-300x169.jpg" alt='A close-up shot of a hand holding a sign that reads "Buy Now, Pay Later."'><div>Source: Shutterstock</div></div><p><strong>Sezzle </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/sezl-stock-quote/"><strong>SEZL</strong></a>) is the small company on this list. The fintech firm has a market cap below $500 million and a P/E ratio of 33. Sezzle operates in the &ldquo;Buy Now Pay Later&rdquo; industry which allows consumers to buy products and services through small monthly installment payments. Total subscribers more than tripled YOY to reach 371,000 in the <a href="https://assets.ctfassets.net/6d085vujy22q/5De425CwZRqPrWBkE4OPtx/e65eac50850633ad1c2f8d859f332dfa/Q1_2024_Presentation.pdf">first quarter</a>. The company also reported a 45.9% YOY increase in the number of transactions.</p>



<p>Those metrics contributed to Sezzle&rsquo;s successful quarter where <a href="https://assets.ctfassets.net/6d085vujy22q/jhhdNdNR1ADmo3jUUlGQe/bc151fae8d50d4e07c7f6879fc14498f/Q1_2024_Earnings_Release.pdf">revenue increased by 35.5% YOY</a>. Net income surged by 364.3% YOY to reach $8.01 million. Sezzle wrapped up the quarter with a net profit margin just above 17%. Soaring profits and encouraging guidance suggest that the stock is reasonably valued. The hidden fintech gem has more than tripled year-to-date. The gains are even more substantial if you go back to October 2023. From that point, shares have soared by more than 800%.&nbsp;</p>



<p>Notably, Sezzle closed out the first quarter with $82.2 million of cash on hand. That means almost 20% of Sezzle&rsquo;s market cap is based on its cash position. The stock looks reasonably priced heading into the rest of the year.</p>



<p><em>On this date of publication, Marc Guberti held long positions in AVGO and SEZL. The opinions expressed in this article are those of the writer, subject to the&nbsp;</em><a href="https://investorplace.com/"><em>InvestorPlace.com</em></a><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines.</em></a></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Marc Guberti is a finance freelance writer at InvestorPlace.com who hosts the Breakthrough Success Podcast. He has contributed to several publications, including the U.S. News &amp; World Report, Benzinga, and Joy Wallet.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/the-3-best-nasdaq-stocks-to-buy-in-august-2024/">The 3 Best Nasdaq Stocks to Buy in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Nasdaq Stocks to Buy in August 2024

Sezzle Inc. (SEZL) Q2 2024 Earnings Call Transcript

Sezzle Inc. (SEZL) just unveiled an announcement. Starting August 13, 2024, Sezzle Inc. will begin sharing an investor presentation to guide discus...

Sezzle Inc. Launches Investor Presentation for Enhanced Communication

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Many corporations have reported earnings over the past few weeks. The steady stream of earnings reports gives investors a better idea of how to value companies and what to expect from them moving forward.</p>



<p>Some <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> continued to excel, posting rising revenue and profit margins. However, other growth stocks demonstrated possible challenges along the horizon. Those corporations often posted decelerating year-over-year (YOY) revenue and net income growth.</p>



<p>Buying and holding reliable corporations allows investors to realize returns and save a lot of time. You don&rsquo;t have to time the market or trade options during the earnings season to achieve long-term financial goals. It&rsquo;s possible to accumulate shares in solid companies and watch your money grow over time.&nbsp;</p>



<p>Some growth stocks do a better job at growing investors&rsquo; money than others, and earnings reports offer clues on which stocks are the winners. Investors may want to monitor these promising growth stocks after they delivered impressive earnings results.&nbsp;</p>



<h2>Meta Platforms (META)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/meta-threads1600-300x169.png" alt="Threads app logo seen on screen. Instagram Threads app is a micro blogging platform, developed by Facebook Meta."><div>Source: Ascannio / Shutterstock.com</div></div><p>Few stocks have delivered the same financial growth as <strong>Meta Platforms</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/meta-stock-quote/"><strong>META</strong></a></span>) while trading at a 26 P/E ratio. Revenue <a href="https://s21.q4cdn.com/399680738/files/doc_financials/2024/q2/Meta-06-30-2024-Exhibit-99-1_Final.pdf">jumped by 22% YOY</a> while net income soared by 73% YOY in the second quarter. Meta Platforms knows how to attract and retain users. The company has 3.27 billion daily active users spread across its social networks. That figure is up by 7% YOY.</p>



<p>Meta Platforms has outperformed the stock market for several years. Shares are up by 49% year-to-date (YTD) and have rallied by 181% over the past five years. The social media giant continues to return capital to shareholders. Investors received $1.27 billion worth of dividends in the quarter. Meta Platforms also invested $6.32 billion into stock buybacks.</p>



<p>The online advertiser has established itself as one of the top choices for businesses. Its targeting capabilities are hard to match, and Meta Platforms continues to retain attention across multiple platforms.</p>



<h2>Sezzle (SEZL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div><p>The &ldquo;Buy Now Pay Later&rdquo; fintech firm is one of the top-performing stocks right now. <strong>Sezzle</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sezl-stock-quote/"><strong>SEZL</strong></a></span>) is up by an <a href="https://finance.yahoo.com/quote/SEZL/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAAFIGdYVs2gBq50NVJvX9k9Ywz4xXHAB2qoxzqm0YnZ8jZgu8kaKXNTKNwmc9YHsj-W2KXbG0s09g67avvcAGyCwBPvwkoCQ1AmAw15TAb9u-cAB-XPdRsWYdDjCDnmH6wwtxVkBe623CToXZu-C8vMENur5T3nfp4C7vkRDZNV--">astonishing 490% YTD and has a $678 million market cap</a>. The hidden gem should extend its gains due to a very promising earnings report.</p>



<p>Sezzle delivered <a href="https://assets.ctfassets.net/6d085vujy22q/6yHHqWHdYCyBzQgvrUcR8T/b0273a1aedbdd3ec3ef4a530979d8350/Q2_2024_Earnings_Release.pdf">60% YOY revenue growth</a> to reach $56 million. Furthermore, net income surged to reach $29.7 million. The company aggressively increased its guidance, now projecting 35%-40% YOY revenue growth instead of 25% YOY revenue growth. Net income is also projected to reach $55.0 million instead of the previous guidance of $30 million.</p>



<p>The net income goal is important for understanding the growth opportunity that Sezzle provides. Assuming Sezzle reaches this goal, it&rsquo;s trading at a forward P/E ratio of approximately 12. This valuation comes form a company that anticipates full-year revenue growth to by as high as 40%. It&rsquo;s also possible for Sezzle to raise its guidance again in the third quarter.</p>



<h2>Deckers Outdoor (DECK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/deckers-outdoor-deck-1600-300x169.jpg" alt="Deckers Outdoor (DECK) logo displayed on smartphone screen"><div>Source: shutterstock.com/Piotr Swat</div></div><p><strong>Deckers Outdoor</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/deck-stock-quote/"><strong>DECK</strong></a></span>) is an athletic apparel company that is gaining market share from its more established rivals. The company has several brands under its umbrella, with HOKA and UGG being the most important ones.&nbsp;</p>



<p>The company <a href="https://ir.deckers.com/news-events/press-releases/press-release/2024/Deckers-Brands-Reports-First-Quarter-Fiscal-Year-2025-Financial-Results/default.aspx">started fiscal 2025</a> on a high note with 22% YOY revenue growth. The company&rsquo;s $825 million revenue came alongside $116 million in net income. That figure is up by 82% YOY, and brought Deckers Outdoor&rsquo;s net profit margin to 14%. Shares are up by 36% YTD and trade at a 29 P/E ratio. Also, the stock is up by 584% over the past five years!</p>



<p>HOKA was a key contributor for total sales. That part of Deckers Outdoor&rsquo;s business grew by 29.7% YOY and brought in $545.2 million in the quarter. That&rsquo;s more than half of the company&rsquo;s total revenue. Deckers Outdoor closed out the quarter with a $1.438 billion cash position and had no outstanding borrowings.</p>



<h2>American Express (AXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/american_express_axp1600-300x169.jpg" alt="the American Express logo etched into wood"><div>Source: First Class Photography / Shutterstock.com</div></div><p><strong>American Express</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/axp-stock-quote/"><strong>AXP</strong></a></span>) offers growth at a reasonable price. The stock trades at an 18 P/E ratio and offers a 1.18% yield while delivering 9% YOY revenue growth in the <a href="https://s26.q4cdn.com/747928648/files/doc_financials/2024/q2/q2-2024-earnings-press-release.pdf">second quarter</a>. Furthermore, net income jumped by 39% YOY, putting more emphasis on the low P/E ratio.</p>



<p>Shares of the credit and debit card issuer have outperformed the <strong>S&amp;P 500</strong> with a 26% YTD gain. And, the stock is up by 90% over the past five years. American Express&rsquo; rising profit margins can help it command a valuation similar to its peers in the future. That development could help American Express stock gain more than 50%, but it can take a while before investors see it in the same light as <strong>Visa</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/v-stock-quote/"><strong>V</strong></a></span>) and <strong>Mastercard</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/ma-stock-quote/"><strong>MA</strong></a></span>). For now, American Express continues to expand its margins and closed out the second quarter with a net profit margin of 20%.</p>



<h2>Intuit (INTU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/intu1600-300x169.png" alt="Person holding cellphone with logo of US financial software company Intuit Inc. (INTU) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Intuit </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/intu-stock-quote/"><strong>INTU</strong></a></span>) offers financial and business software that helps people with several tasks, such as filing taxes, organizing their finances and growing their companies. Those software products result in recurring revenue that has helped the company outperform the stock market for several years. While shares are only up by 4% YTD, they have rallied by 132% over the past five years. Also, Intuit has a 0.57% yield and has maintained a high dividend growth rate for several years.</p>



<p>The fintech firm delivered 12% YOY revenue growth in the <a href="https://investors.intuit.com/_assets/_d2e5db6eb85e1b894c09ba50ff1bce49/intuit/news/2024-05-23_Intuit_Reports_Strong_Third_Quarter_Results_and_1188.pdf">third quarter of fiscal 2024</a>. The company&rsquo;s $6.7 billion in revenue prompted it to raise guidance for fiscal 2024. Notably, Credit Karma posted an 8% YOY revenue growth rate after having a negative growth rate for several quarters. Consumer Group revenue and Small Business and Self-Employed Group revenue increased by 9% YOY and 18% YOY, respectively. TurboTax Live revenue grew by 17% YOY and represented more than one-third of Consumer Group revenue.</p>



<h2>Chipotle (CMG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/cmg1600-1-300x169.png" alt="Chipolte Mexican Grill sign. Chipolte is a chain of casual dining restaurants specializing in burritos and tacos. CMG stock"><div>Source: Ken Wolter / Shutterstock.com</div></div><p><strong>Chipotle </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/cmg-stock-quote/"><strong>CMG</strong></a></span>) has been outperforming the stock market for a while. It&rsquo;s gains resemble a tech company, as shares are up by 24% year-to-date and have surged by 2442% over the past five years. The corporation recently completed a 50-for-1 stock split which has made shares more accessible to options traders. That development should increase Chipotle&rsquo;s volatility and potential gains.</p>



<p>The fast food restaurant chain reported <a href="https://ir.chipotle.com/2024-07-24-CHIPOTLE-ANNOUNCES-SECOND-QUARTER-2024-RESULTS">18.2% YOY revenue growth</a> in the second quarter and remains on track to open 285-315 restaurants this year. Chipotle opened 52 company-operated restaurants and an international licensed restaurant during the quarter. Net income increased by 33.3% YOY.&nbsp;</p>



<p>While these results are good in most quarters, they&rsquo;re even better in this quarter. Several fast food restaurants have reported slower sales as consumers pull back on purchases. Chipotle&rsquo;s revenue growth during this economic environment is a strong testament to its pricing power and status as a healthier fast food restaurant chain than average.</p>



<h2>Alphabet (GOOG, GOOGL)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/alphabet_googl.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/alphabet_googl-300x169.png" alt="Alphabet (GOOGL) - Quantum Computing Stocks to Buy"></a><p><strong>Alphabet</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/goog-stock-quote/"><strong>GOOG</strong></a></span>, NASDAQ:<span><a href="https://investorplace.com/stock-quotes/googl-stock-quote/"><strong>GOOGL</strong></a></span>) is the leading online advertiser. It offers top-tier targeting capabilities across several channels, such as Google, YouTube and websites that enable Google Adsense. The tech giant has rallied by 17% YTD and has surged by 178% over the past five years. The stock trades at a 24 P/E ratio and has a 0.49% yield.&nbsp;</p>



<p>Google&rsquo;s parent company delivered 14% YOY revenue growth in the <a href="https://www.abc.xyz/assets/19/e4/3dc1d4d6439c81206370167db1bd/2024q2-alphabet-earnings-release.pdf">second quarter</a> while net income increased by 29% YOY. Alphabet closed out the quarter with a 27.9% net profit margin.&nbsp;</p>



<p>Artificial intelligence is helping the stock, but its valuation offers a good margin of safety. Investors can see the impact of AI within the company&rsquo;s rising Google Cloud revenue. More than 10% of Alphabet&rsquo;s total revenue came from Google Cloud, and its revenue growth outpaced advertising growth. Alphabet is the <a href="https://www.statista.com/chart/18819/worldwide-market-share-of-leading-cloud-infrastructure-service-providers/">third largest cloud provider</a> and looks poised to gain market share in the upcoming quarters.</p>



<p><em>On this date of publication, Marc Guberti held long positions in SEZL, DECK, and GOOG. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Marc Guberti is a finance freelance writer at InvestorPlace.com who hosts the Breakthrough Success Podcast. He has contributed to several publications, including the U.S. News &amp; World Report, Benzinga, and Joy Wallet.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/7-growth-stocks-to-buy-on-encouraging-earnings-results/">7 Growth Stocks to Buy on Encouraging Earnings Results</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Growth Stocks to Buy on Encouraging Earnings Results

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Sezzle</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sezl-stock-quote/"><strong>SEZL</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Sezzle reported earnings per share of $2.17. This was above the analyst estimate for EPS of 83 cents.</li><li>The company reported revenue of $55.97 million.</li><li>This was 29.11% better than the analyst estimate for revenue of $43.35 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div>	<p>The post <a href="https://investorplace.com/earning-results/2024/08/sezl-stock-earnings-sezzle-for-q2-of-2024/">SEZL Stock Earnings: Sezzle Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SEZL Stock Earnings: Sezzle Beats EPS, Beats Revenue for Q2 2024

Sezzle Inc. (SEZL) has provided an update. Sezzle Inc. has entered into a five-year strategic partnership with WebBank, beginning a program where W...

Sezzle Inc. Forges Strategic Alliance with WebBank for Financing Products

Northland Securities analyst Michael Grondahl maintained a Buy rating on Sezzle Inc. (SEZL – Research Report) today and set a price target of $150....

Comments

Sezzle

Noticias

Últimas noticias sobre Sezzle (NASDAQ:SEZL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL